Tag: monoclonal antibody
Sun Pharma’s phase 3 trials of ILUMYA support potential U.S. submission...
Both pivotal studies met their primary endpoint with statistically significant improvements based on ACR20 response rates at Week 24 with tildrakizumab 100 mg (ILUMYA) compared to placebo
Syngene acquires its first manufacturing facility in the US
Biologics drug substance facility in Baltimore expected to enhance global innovator flexibility
Cadila Pharma expands its oncology portfolio with monoclonal antibody, Tarzed
TARZED is considered safe and more efficacious compared to conventional treatment medicines for breast cancer